,K ϩ -ATPase by covalent binding to the sulfhydryl group of H ϩ ,K ϩ -ATPase, resulting in the long-lasting inhibition of gastric acid secretion. 1) They are now widely used for the treatment of gastric acid-related diseases such as peptic ulcer and gastroesophageal reflux disease. 2, 3) Reversible acid pump antagonists (APAs), the other class of proton pump inhibitors, act by potassium competitive inhibition and reversible binding to the gastric proton pump. 4) From their competitive inhibition of potassium, they could also be called potassium competitive acid blockers.
5) The major classes of APAs are imidazopyridine [6] [7] [8] and acyl quinoline derivatives. [9] [10] [11] 7-(4-Fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyrrolo [2,3-d] pyridazine (CS-526) is a novel acid suppressant which is different from PPIs and the aforementioned APAs in that its chemical structure includes a pyrrolopyridazine structure. 12) We have shown the potent and reversible inhibitory properties of CS-526 against porcine H ϩ ,K ϩ -ATPase without any covalent binding formation. The potent gastric acid inhibitory effects and antiulcer efficacy of CS-526 have also been shown in rats and the efficacy of CS-526 is comparable to those of PPIs such as omeprazole, lansoprazole and rabeprazole. 12) Well-known problems resulting from chronic usage of long-lasting acid inhibitors are induction of hypergastrinemia [13] [14] [15] [16] [17] and rebound gastric acid hypersecretion. [18] [19] [20] We confirmed that subchronic (14-d) treatment of lansoprazole at a dose of 30 mg/kg/d showed significant elevation of the serum and antrum gastrin levels and rebound gastric acid hypersecretion after cessation of the treatment in rats. However, while CS-526 had a weak effect on serum gastrin elevation and rebound gastric acid hypersecretion, it nevertheless showed an acid suppressive effect comparable to that of lansoprazole. 21) There are a great number of reports in which the effects of agents on gastric acid secretion are evaluated in rats and dogs. However, in terms of monkeys, there are only a few reports regarding gastric acid status [22] [23] [24] [25] [26] [27] and less than 10 reports of pharmacodynamic studies. [28] [29] [30] [31] [32] [33] [34] However, we think it would be meaningful to obtain data from non-human primates because of their phylogenetic similarities with human beings.
In the present study, to further clarify the acid suppressive effect of CS-526, we studied non-human primates (cynomolgus monkeys) utilizing intragastric pH-metry, which is widely used in clinical studies. Simultaneously, we measured the plasma concentration of CS-526 and its active metabolite to study the relation between the pharmacodynamic and pharmacokinetic parameters. 12) Briefly, the ATPase was prepared by the method of Im and Blakeman 35) with some modifications. An enzyme sample (40 mg/ml) extracted from porcine gastric mucosa was incubated at 37°C in 1 ml of a medium consisting of 40 mM Tris/acetic acid, pH 7.4, 2 mM MgCl 2 , 2 mM ATP. The H ϩ ,K ϩ -ATPase activity was determined in the presence of 10 mM KCl. After preincubation with the compounds for 60 min, the inorganic phosphate released from ATP for 20 min was determined by the methods of Fiske and Subbarow 36) as an activity of ATPase. Animals All the procedures regarding animal care and experiments were performed at Shin Nippon Biomedical Laboratories, Ltd. (Kagoshima, Japan) in compliance with the animal experimental guidelines established in the organization.
MATERIALS AND METHODS

Chemicals
Five male cynomolgus monkeys (purpose-bred, B-virus negative, Guangxi Primate Center of China, Guangxi, China) weighing 2.6-3.3 kg were used. The animals were given tap water ad libitum. Each animal was housed in a stainless steel cage (according to the regulation of United States Department of Agriculture) maintained at room temperature of 26Ϯ2°C and with humidity of 50Ϯ10% under a 12 h light/dark cycle (lighting period: 6:00 a.m.-6:00 p.m.). Their gastric pH in an unfed status was confirmed to be between 1 and 3 during the acclimatization period.
Study Design The animals were divided into 3 groups and administered CS-526 in a crossover manner at 1 week intervals, as shown in Table 1 . The doses were 3.0, 10 and 30 mg/kg for the oral administration and 0.3, 1.0 and 3.0 mg/kg for the intravenous administration.
Dosing Suspension and Solution CS-526 was suspended in 0.5% (w/v) sodium carboxymethyl cellulose aqueous solution at concentrations of 1.5, 5.0 and 15 mg/ml for 3.0, 10 and 30 mg/kg in the oral administration, respectively. For the intravenous administration, CS-526 was dissolved in a mixed solution of N,N-dimethylacetamide, 0.1 mol/l hydrochloride and saline (composition ratio, 10 : 5 : 85) at concentrations of 0.15, 0.5 and 1.5 mg/ml for 0.3, 1.0 and 3.0 mg/kg, respectively. The suspension or solution was administered at 2 ml per kg body weight for the oral and intravenous administrations, respectively.
Intragastric pH-Metry in Cynomolgus Monkeys
The animals were given 108 g of standard diet for non-human primates (Harlan Teklad Global Diet 2055, Harlan Tekrad, Inc., Indianapolis, IN, U.S.A.) every day at around 1:00 p.m. and the remnants were collected at 3:00 p.m., except on the day of the intragastric pH measurement. On the day of the intragastric pH measurement, 48 g of the diet was given after the blood sampling at 8 h after the administration and the remnants were collected 2 h after the feeding.
The intragastric pH was measured at 0.5 h and immediately before the CS-526 administration. Thereafter, the intragastric pH was also measured at 0.5, 1, 2, 3, 4, 5, 6, 7, 8 and 24 h after the administration. At the measuring time points, each animal was restrained for up to a maximum of 5 min in a special cage which was designed to limit its movement without any large stress. A pH-probe (diameter 1.5 mm, Multi-Use pH Catheter, 839100, Synectics Medical, Barcarena, Portugal) connected to an ambulatory pH-monitor (Digitrapper MkIII, Synectics Medical AB, Stockholm, Sweden) was introduced into the stomach via the transnasal pathway. To keep the appropriate position of the probe, we marked the position of the nasal cavity on the probe with a felt tipped pen at the first measuring period before CS-526 administration. And if the indicated pH value was above 3.0, 
the probe was drawn out and reintroduced once more. The measuring time period was about 2 min and the median pH value within the period was adopted as the intragastric pH value for the time point. After each measurement, the animals were returned to their home cages.
Measurement of Plasma Compound Level
Blood samples at the volume of 1.2 ml each were withdrawn via the femoral vein with a heparinized syringe immediately before the administration and 0.25, 0.5, 1, 2, 3, 4, 8 and 24 h after the administration. Plasma samples were taken after centrifugation (3000 rpm, 4°C, 10 min) and were stored under Ϫ20°C until measurement.
After thawing at the time of use, the plasma was centrifuged (3000 rpm, 4°C, 10 min). Then 0.1 ml of plasma was mixed with 0.1 ml of acetonitrile and 0.2 ml of internal standard (R-127788) acetonitrile solution and the mixture was centrifuged for 3 min at 12000 rpm at 4°C. Supernatant (10 ml) was applied for liquid chromatography tandem mass spectrometry (LC/MS/MS). The LC/MS/MS conditions are shown in Table 2 .
Data Analysis For the pharmacodynamic parameters, the time period in which the intragastric pH was 4.0 or more (Time pHՆ4.0 ) and the median pH were calculated for 24 h after the administration. The time at which the intragastric pH intersected 4.0 was interpolated with the adjacent measuring time points showing the intragastric pH above and below 4.0.
For the pharmacokinetic parameters, noncompartmental pharmacokinetic analysis was performed using WinNonlin (Pharsight Co., Mountain View, CA, U.S.A.). The maximum plasma concentration of compound (C max ) and the time at C max (T max ) were determined from the observed values. The elimination half life (T 1/2 ) and the area under the curve of the longitudinal course of concentration from 0 to 24 h (AUC 0-24 h ) were calculated using WinNonlin. In these calculations, a concentration below the lower limit of quantification (Ͻ0.5 ng/ml; ϽLOQ) was treated as 0.
The mean and the standard error (S.E.) of these parameters were calculated using Microsoft Excel ® (Microsoft, Redmond, WA, U.S.A.).
Microsoft Excel and SAS
® System for Windows (SAS Institute, Cary, NC, U.S.A.) were used for the following statistical procedures.
The concentration at which the compound exerted 50% inhibition (IC 50 ) against H ϩ ,K ϩ -ATPase was calculated from a concentration-inhibition rate curve prepared from the relation of the individual inhibition rate at each concentration level versus the logarithmic concentration by the leastsquares method. The 95% confidence intervals (95% CI) were obtained based on Fieller's theorem.
The dose-response relationship of the pharmacodynamic parameters was analyzed by Pearson correlation analysis. The ratio of the pharmacodynamic activity between the oral and intravenous administrations was analyzed by parallel line analysis.
The Pearson correlation analysis was performed between the pharmacodynamic parameters and the logarithmic AUC 0-24 h of CS-526, R-130185 and the active component. One of the animals given 0.3 mg/kg of CS-526 intravenously did not show any detectable amount of R-130185. As a result, the AUC 0-24 h of R-130185 of the animal was omitted in the correlation analysis. Table 3 . The inhibitory activities of CS-526 and R-130185 were almost the same with IC 50 of 53 nM and 57 nM, respectively. R-130186, in contrast, was almost inactive and the IC 50 was more than 100 mM.
RESULTS
Effects of Metabolites of CS-526 against H
Effects of CS-526 on Intragastric pH in Cynomolgus Monkeys
The intragastric pH of cynomolgus monkeys elevated immediately after administration of CS-526 (Fig. 2) . In particular, with the oral dose 2, 3 and 4 out of 5 monkeys showed an intragastric pH above 4.0 at 0.5 h after the administration at doses of 3.0, 10 and 30 mg/kg, respectively. In the intravenous administration, a somewhat slower onset was observed. Two, 0 and 2 out of 5 monkeys showed an intragastric pH above 4.0 at 0.5 h after the administration at doses of 0.3, 1.0 and 3.0 mg/kg, respectively. The mean intragastric pH was maintained above 4.0 for 8 h at oral doses of 10 and 30 mg/kg of CS-526 and two peaks of the mean intragastric pH were observed during the period. The effect after intravenous administration also showed a biphasic pattern in which the mean intragastric pH was raised above 4.0 by 4 or 5 h after the administration. It went below 4.0 once and thereafter remained above 4.0 again. These biphasic patterns of mean intragastric pH elevation were not derived artificially from asynchronous peak timing. Multiple, two or three, 2012 Vol. 32, No. 12 peaks of intragastric pH were also observed in individual animals and the number of animals showing multiple peaks of intragastric pH increased in accordance with the increment of the dose. One, 4 and 4 out of 5 animals after oral administration at doses of 3.0, 10 and 30 mg/kg and 2, 3 and 4 out of 5 animals after intravenous administration at doses of 0.3, 1.0 and 3.0 mg/kg showed multiple peaks of intragastric pH, respectively. The pharmacodynamic parameters, Time pHՆ4.0 and median pH within 24 h after CS-526 administration are summarized in Table 4 . Time pHՆ4.0 increased in a dose-dependent manner in the oral administration (pϭ0.0292) but not in the intravenous administration (pϭ0.1901, Fig. 3A) . On the other hand, the median pH increased in a dose-dependent manner in the intravenous administration (pϭ0.0491) but not in the oral administration (pϭ0.1283, Fig. 3B ). In both parameters (Time pHՆ4.0 and median pH), parallel line analysis revealed that the lack of parallelism was not significant (pϭ0.4067 for Time pHՆ4.0 , pϭ0.9973 for median pH) and the efficacy ratio (IV/PO) was 3.3 (95% CI: 0.048-14) and 4.1 (95% CI: 0.060-19), respectively.
Pharmacokinetics Profile of CS-526 in Cynomolgus Monkeys
The plasma concentration of CS-526 (Fig. 4A) and R-130185 (Fig. 5A ) increased after oral administration of CS-526 at doses of 3.0, 10 and 30 mg/kg. Three and 2 out of 5 monkeys showed two peaks of plasma CS-526 concentration at doses of 10 and 30 mg/kg, respectively. The pharmacokinetic parameters are shown in Table 5 . T 1/2 of CS-526 at a dose of 10 mg/kg was prolonged (18.15 h) because of variation in the results, such as 2 out of 5 animals showed the T 1/2 over 30 h with ambiguous peak. Without these two animals, T 1/2 (meanϮS.E., h) was 7.053Ϯ2.662. As the inhibitory activity against H (Fig. 6) .
Except for one animal which did not show any detectable amount of R-130185 after administration of the lowest dosage, CS-526 (Fig. 4B ) and R-130185 (Fig. 5B) were observed after the intravenous administration of CS-526 at doses of 0.3, 1.0 and 3.0 mg/kg and the pharmacokinetic parameters are shown in Table 6 . Even R-130185 was observed at doses of 0.3 and 1.0 mg/kg, the level was close to lower limit of quantification. Therefore T 1/2 of R-130185 at the dosages would be derived from some anomaly. The AUC 0-24 h ratio of R-130185 to CS-526 was remarkably small in comparison with that in the oral administration. AUC 0-24 h (meanϮS.E., ng · h · ml Ϫ1 ) of the active component was 116.5Ϯ6.386 (0.3 mg/kg), 417.0Ϯ30.71 (1.0 mg/kg) and 1242Ϯ83.82 (3.0 mg/kg) and the linearity was confirmed in this dose range (Fig. 6) . The absolute bioavailability of the active component was estimated to be approximately 1%.
Correlation of Pharmacodynamic and Pharmacokinetic Parameters The correlations between the pharmacodynamic parameters (Time pHՆ4.0 and median pH) and AUC 0-24 h of CS-526, R-130185 or the active component are shown in Fig. 7 . In the oral administration, significant correlation was observed between Time pHՆ4.0 and AUC 0-24 h of CS-526, R-130185 or the active component (Figs. 7A-C) . In addition, correlation between median pH and AUC 0-24 h of CS-526 was also significant (Fig. 7D) . Table 5 . Pharmacokinetic Parameters of CS-526 and Its Active Metabolite R-130185 after Oral Administration of CS-526 (MeanϮS.E.) On the other hand, in the intravenous administration, there was no significant correlation between the pharmacodynamic and pharmacokinetic parameters.
To clarify the reason for these differences between oral and intravenous administration, we further analyzed the correlation between the mean intragastric pH values and the corresponding mean plasma concentrations of the active component. Diagrammatizing the mean intragastric pH against the corresponding mean plasma concentration of the active component revealed that the mean intragastric pH seemed to correlate with the mean plasma concentration of the active component in the oral administration (Fig. 8A) . However, in the intravenous administration, the mean intragastric pH of the early time points (0.5 and 1 h after the administration) deviated from the predicted correlation pattern (Fig. 8B) .
DISCUSSION
In vivo evaluations of the gastric acid inhibitory properties of acid suppressive agents in rats and dogs have been widely performed. Although the data from non-human primates would be useful for the prediction of clinical study results due to their phylogenetic similarities, the background knowledge of gastric acid secretion in primates is still lacking. There are only a few reports regarding the physiologic state of gastric acid secretion [22] [23] [24] [25] [26] [27] and less than 10 reports of pharmacodynamic studies. [28] [29] [30] [31] [32] [33] [34] In these pharmacodynamic studies, gastric juice or infused wash solution was collected from acute gastric fistulae in anesthetized animals or nasogastric tubes in monkey chair restrained animals, respectively. With these restrictions in the experimental conditions, the duration of measurement was up to a maximum of 9 h. In addition, there is difficulty in showing a definite dose-response relationship of acid suppressants in basal gastric acid secretions. Therefore, in some of the experiments of these studies, acid stimuli such as histamine or histamine H 2 -receptor agonist were used to obtain more quantitative data. Meanwhile, we used periodic intragastric pH-metry in conscious animals without any acid stimuli. With some modifications of the timing and the amount of diet, we could measure the intragastric pH for 24 h. In clinical situations, intragastric or esophageal pH-metry is used for the evaluation of the pathophysiologic state of acid-related disease and the pharmacodynamic study of acid suppressants. Time pHՆ4.0 and median or mean pH are widely used as the parameters to evaluate the antisecretory efficacy of gastric acid suppressant. [37] [38] [39] We also used these parameters in the present study to evaluate the gastric acid inhibitory properties of CS-526 in cynomolgus monkeys. Despite the relatively small measuring time points (11 points/24 h) which might cause insignificant dose-response relationship in Time pHՆ4.0 and median pH after intravenous and oral administration, respectively, these parameters showed significant dose-response relationship in the other route of administration. Though we could not confirm significant dose-response relationship under all the conditions used, we think that these parameters would generally be sufficient to evaluate the gastric acid inhibitory efficacy of CS-526.
In this crossover study, we did not check the effect of vehicle (0.5% CMC). However, the background data from other cynomolgus monkeys have been obtained at the same feeding condition and with the same method that we used in this study. In 6 animals selected by unfed gastric pH below 3 in the acclimatization period, 5 animals (83%) showed gastric pH less than 5.0 during the measurement period (from 0 to 24 h after vehicle administration) with median pH (meanϮ S.E. for 24 h of 6 animals) of 2.0Ϯ0.2 and Time pHՆ4.0 (meanϮS.E., h) of 0.4Ϯ0.3 (data not shown). A recent study has revealed that the gastric pH of unfed cynomolgus monkeys is generally low and that at least 60% of the animals show less than pH 5 during a 24 h measurement period with the median pH between 1 and 3. 25) There was only a small difference in the ratio of animals showing low gastric pH compared to our background data. Although the exact dose which showed a significant effect was not clarified, the inhibitory effect of CS-526 against gastric acid secretion in cynomolgus monkeys was obvious after oral or intravenous administration.
In the present study, the onset of action after the CS-526 administration was somewhat faster in oral administration than in intravenous administration despite the higher plasma level of CS-526 and active component after intravenous administration. We previously showed that CS-526 may act on parietal cells by two routes: one route is absorption from the small intestine and the other is direct permeation through the gastric mucosa from the gastric lumen.
12) H ϩ ,K ϩ -ATPase, an active site of CS-526, is localized on the apical membrane of the parietal cells. In addition, the putative APA binding site of H ϩ ,K ϩ -ATPase, which was suspected to be a minute active site of CS-526, is the luminal side of the apical membrane. 40 ) Therefore, we speculated that a compound which is rich in gastric lumen would be able to reach the active site more easily and rapidly than that from general circulation via the intercellular or intracellular routes.
The driving force of disposition of CS-526 from general circulation to the gastric mucosa would be a gradient of environmental pH. This disposition is known as the pH-partition hypothesis, which states that a basic compound tends to concentrate in a low pH environment and that an acidic compound tends to concentrate in a high pH environment. Benzimidazole derivative proton pump inhibitors are basic compounds which demonstrate a pH-dependent drug distribution based on the pH-partition hypothesis and accumulate in a lower pH environment such as the secretory canaliculi of parietal cells. As CS-526 and R-130185 are thought to be basic compounds (unpublished data), the localized distribution would be driven into the low pH gastric lumen. Once they have been secreted into the gastric lumen, the compounds might be reabsorbed afterwards. The longer half life and two peaks of plasma concentration of CS-526 in some
